Association between CYP2E1 polymorphisms and susceptibility to prostate cancer.
Several genetic alterations have been associated with sporadic prostate cancer (PCa). In this study, the association between RsaI and DraI polymorphisms of CYP2E1 and PCa risk was analysed in a case-control study of 227 individuals using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Regarding DraI polymorphisms, the DD genotype is over-represented in PCa cases when compared with the control group (odds ratio (OR) 2.12; 95% confidence interval (CI) 1.11-4.05; P=0.022). Regarding the RsaI polymorphism, no significant differences were found. The results of this study indicate that DraI polymorphisms of the CYP2E1 gene may be associated with a twofold increased risk for the development of PCa.
Ferreira
P M
PM
Molecular Oncology Unit, Instituto Português de Oncologia do Porto, Portugal. paulamsferreira@mail.com
Medeiros
R
R
Vasconcelos
A
A
Costa
S
S
Pinto
D
D
Morais
A
A
Oliveira
J
J
Lopes
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D014408:Biomarkers, Tumor / Q000097:blood; D016022:Case-Control Studies; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics*; D005787:Gene Frequency / Q000235:genetics; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000453:epidemiology / Q000235:genetics*; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D011174:Portugal / Q000453:epidemiology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000378:metabolism; D044469:Racial Groups / Q000235:genetics; D012307:Risk Factors; D013223:Statistics as Topic
D014408:Biomarkers, Tumor; D005819:Genetic Markers; D019392:Cytochrome P-450 CYP2E1; D017430:Prostate-Specific Antigen